Bone matters: Defining the burden of skeletal disease in telomere biology disorders

J Jane Koo (1Cincinnati Children's Hospital Medical Center, Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati, United States) L Lindsey N. Hornung (3Cincinnati Children's Hospital Medical Center, Division of Biostatistics and Epidemiology, Cincinnati, United States) J Jonathan Howell (1Cincinnati Children's Hospital Medical Center, Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati, United States) E Ethan Lawhorn (1Cincinnati Children's Hospital Medical Center, Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati, United States) D Dawn Comstock (4Brigham and Women's Hospital, Harvard Medical School, Department of Medicine, Boston, United States) C Christopher Reilly (6Division of Hematologic Malignancies, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, United States) A Alejandro Ferrer (4Mayo Clinic, Rochester, United States) A Abhishek Mangaonkar (1Mayo Clinic, Rochester, United States) B Bianca Barredo (9University of Wisconsin Carbone Cancer Center, Madison, United States) J Jane Churpek (2University of Wisconsin-Madison, Madison, United States) F Fabian Beier (5Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf, Germany) L Linda Frazier (10University of Pittsburgh, Department of Pediatrics, Pittsburgh, United States) P Pamela Vincent (10University of Pittsburgh, Department of Pediatrics, Pittsburgh, United States) P Paul Szabolcs (10University of Pittsburgh, Department of Pediatrics, Pittsburgh, United States) J Jessica Uhrich (13St. Jude Children's Research Hospital, Department of Hematology, Memphis, United States) M Marcin Wlodarski (2St. Jude Children's Research Hospital, Department of Hematology, Memphis, United States) N Nicholas Gloude (14Rady Children's Hospital San Diego, Division of Pediatric Hematology/Oncology, San Diego, United States) H Helena Yu D Divya Koura (6University of California San Diego Moores Cancer Center, San Diego, CA) T Tanim Jain (13Moores Cancer Center, San Diego, United States) O Orna Steinberg-Shemer (16Tel Aviv University, Gray Faculty of Medical and Health Sciences, Tel Aviv, Israel) C Christen Ebens (1University of Minnesota, Department of Pediatrics, Division of Pediatric Blood and Marrow Transplantation & Cellular Therapy, Minneapolis, United States) P Paul Wratkowski (19University of Minnesota, Division of Blood and Marrow Transplant & Cellular Therapy, Department of Pediatrics, Minneapolis, United States) S Soundarya Avantsa (20National Institutes of Health, Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, Bethesda, United States) E Emma Groarke (1National Institutes of Health, National Heart, Lung, and Blood Institute (NHLBI), Bethesda, United States) B Bhavisha Patel (1National Institutes of Health, National Heart, Lung, and Blood Institute (NHLBI), Bethesda, United States) S Sharon Savage (20National Institutes of Health, Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, Bethesda, United States) N Neelam Giri (3National Institutes of Health, Clinical Genetics Branch, National Cancer Institute, Bethesda, United States) K Kasiani Myers (1Cincinnati Children's Hospital Medical Center, Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati, United States)

Abstract

Abstract Introduction: Telomere biology disorders (TBDs) are caused by germline pathogenic or likely pathogenic variants in telomere maintenance genes and result in multisystem manifestations, including impaired bone health. Patients with TBDs experience reduced bone mineral density (BMD), avascular necrosis, and increased rates of fragility fractures. However, the underlying mechanisms of these bone complications remain poorly understood, and no TBD-specific treatments for bone health currently exist. Our objective was to characterize the clinical features, management, and outcomes of TBD-related bone health issues, including fractures and reduced BMD. Methods: We conducted a retrospective, multicenter, international cohort study using data from 232 patients with TBDs enrolled across 12 centers participating in the Clinical Care Consortium of Telomere-Associated Ailments. Medical records were reviewed for fracture history and BMD assessments by dual-energy X-ray absorptiometry (DXA). The primary endpoint was fracture incidence; secondary endpoints included BMD assessment and fracture management. Data were stratified by pediatric (≤18 years) and adult (>18 years) age groups. Analyses were based on data availability; specific denominators are provided where applicable. Result: Data were available for 53 (23%) pediatric and 179 (77%) adult patients. TERT mutations were the most frequently identified variants in both groups (28% pediatric, 23% adult). Fractures occurred in 25% (13/53) of pediatric patients and 35% (62/178) of adults. In contrast, fractures are estimated to occur in 10-15% of the general pediatric population. The median age at first fracture was 8.2 years (range 2.5–17) in children and 29.2 years (range 18.3–66.9) in adults. Among those with fracture data (n=20 pediatric, n=22 adult), fragility fractures were more common in adults (57%) versus predominantly traumatic fractures in children (61%). Multiple fractures occurred in 65% of affected pediatric patients and 45% of affected adults. Fracture management also differed: non-surgical treatments were used in 60% of pediatric fractures (n=12/20) versus 36% (n=8/22) of adult fractures; surgical interventions were more common in adults (36%). The inheritance pattern (autosomal dominant versus recessive or X-linked) was not associated with fracture risk but the subset of patients with CTC1 mutations were associated with increased fracture risk (n=5 of 124 patients with fracture history, 4% vs n=2 of 247 patients with no fracture history, 0.8%; p=0.04). We also assessed whether vascular manifestations were associated with fracture risk comparing patients with and without fractures. Pulmonary arteriovenous malformations (AVMs) were significantly more common in patients with fractures (17%, 7/42) versus those without (5.4%, 6/112; p=0.04). No significant differences were found in rates of retinal vasculopathy or hemorrhage (13% vs 7.2%, p=0.23) or gastrointestinal bleeding (22% vs 16%, p=0.35). DXA data were available for 171 patients (22 pediatric, 149 adult). The median age at first DXA was 11.4 years (range 4–17.7) for children and 58.2 years (range 20.8–79.4) for adults. Among pediatric patients, the median lumbar spine Z-score was –1.2 (IQR –3.0 to –0.2, n=18), with 39% (7/18) showing a Z-score < –2. Among adults, the median femoral neck T-score was –1.1 (IQR –1.7 to –0.5, n=118), with 21% (29/138) demonstrating T-scores < –2, indicating low BMD. Conclusions: Fractures and reduced BMD are common in both pediatric and adult patients with TBDs, with a substantial burden of early-onset and recurrent fractures. Our findings underscore the importance of early bone health screening and surveillance in TBDs and suggest a possible link between vascular abnormalities and skeletal fragility in this population that requires further study.

Article Details

Journal Blood
Volume / Issue Vol. 146, Issue Supplement 1
Published November 03, 2025
Pages 6747-6747
ISSN 0006-4971
Publisher Elsevier BV

Journal Info

Blood

Elsevier BV

ISSN: 0006-4971 Health Sciences

Authors (29)

J

Jane Koo

1Cincinnati Children's Hospital Medical Center, Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati, United States

L

Lindsey N. Hornung

3Cincinnati Children's Hospital Medical Center, Division of Biostatistics and Epidemiology, Cincinnati, United States

J

Jonathan Howell

1Cincinnati Children's Hospital Medical Center, Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati, United States

E

Ethan Lawhorn

1Cincinnati Children's Hospital Medical Center, Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati, United States

D

Dawn Comstock

4Brigham and Women's Hospital, Harvard Medical School, Department of Medicine, Boston, United States

C

Christopher Reilly

6Division of Hematologic Malignancies, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, United States

A

Alejandro Ferrer

4Mayo Clinic, Rochester, United States

A

Abhishek Mangaonkar

1Mayo Clinic, Rochester, United States

B

Bianca Barredo

9University of Wisconsin Carbone Cancer Center, Madison, United States

J

Jane Churpek

2University of Wisconsin-Madison, Madison, United States

F

Fabian Beier

5Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf, Germany

L

Linda Frazier

10University of Pittsburgh, Department of Pediatrics, Pittsburgh, United States

P

Pamela Vincent

10University of Pittsburgh, Department of Pediatrics, Pittsburgh, United States

P

Paul Szabolcs

10University of Pittsburgh, Department of Pediatrics, Pittsburgh, United States

J

Jessica Uhrich

13St. Jude Children's Research Hospital, Department of Hematology, Memphis, United States

M

Marcin Wlodarski

2St. Jude Children's Research Hospital, Department of Hematology, Memphis, United States

N

Nicholas Gloude

14Rady Children's Hospital San Diego, Division of Pediatric Hematology/Oncology, San Diego, United States

H

Helena Yu

D

Divya Koura

6University of California San Diego Moores Cancer Center, San Diego, CA

T

Tanim Jain

13Moores Cancer Center, San Diego, United States

O

Orna Steinberg-Shemer

16Tel Aviv University, Gray Faculty of Medical and Health Sciences, Tel Aviv, Israel

C

Christen Ebens

1University of Minnesota, Department of Pediatrics, Division of Pediatric Blood and Marrow Transplantation & Cellular Therapy, Minneapolis, United States

P

Paul Wratkowski

19University of Minnesota, Division of Blood and Marrow Transplant & Cellular Therapy, Department of Pediatrics, Minneapolis, United States

S

Soundarya Avantsa

20National Institutes of Health, Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, Bethesda, United States

E

Emma Groarke

1National Institutes of Health, National Heart, Lung, and Blood Institute (NHLBI), Bethesda, United States

B

Bhavisha Patel

1National Institutes of Health, National Heart, Lung, and Blood Institute (NHLBI), Bethesda, United States

S

Sharon Savage

20National Institutes of Health, Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, Bethesda, United States

N

Neelam Giri

3National Institutes of Health, Clinical Genetics Branch, National Cancer Institute, Bethesda, United States

K

Kasiani Myers

1Cincinnati Children's Hospital Medical Center, Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati, United States